Citadel Advisors
ADMA icon

Citadel Advisors’s ADMA Biologics ADMA Stock Holding History

Citadel Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
120,100
+9,500
+9% +$150K ﹤0.01% 7477
2025
Q4 		$2.02M Sell
110,600
-120,400
-52% -$2.03M ﹤0.01% 5892
2025
Q3 		$3.39M Sell
231,000
-14,000
-6% -$240K ﹤0.01% 5077
2025
Q2 		$4.46M Buy
245,000
+101,700
+71% +$2.07M ﹤0.01% 4319
2025
Q1 		$2.84M Buy
143,300
+5,200
+4% +$89.9K ﹤0.01% 4866
2024
Q4 		$2.37M Buy
138,100
+89,800
+186% +$1.69M ﹤0.01% 5284
2024
Q3 		$966K Buy
48,300
+37,100
+331% +$577K ﹤0.01% 6938
2024
Q2 		$125K Sell
11,200
-1,600
-13% -$13.4K ﹤0.01% 10597
2024
Q1 		$84.5K Buy
12,800
+8,800
+220% +$48.1K ﹤0.01% 11586
2023
Q4 		$18.1K Sell
4,000
-5,700
-59% -$21.1K ﹤0.01% 12703
2023
Q3 		$34.7K Sell
9,700
-57,800
-86% -$222K ﹤0.01% 12158
2023
Q2 		$249K Sell
67,500
-13,100
-16% -$48.6K ﹤0.01% 9413
2023
Q1 		$267K Buy
80,600
+4,500
+6% +$15.6K ﹤0.01% 9613
2022
Q4 		$295K Buy
76,100
+6,100
+9% +$18.8K ﹤0.01% 9357
2022
Q3 		$170K Sell
70,000
-4,200
-6% -$10.1K ﹤0.01% 10571
2022
Q2 		$147K Buy
74,200
+8,800
+13% +$17.3K ﹤0.01% 11003
2022
Q1 		$120K Sell
65,400
-19,100
-23% -$29.8K ﹤0.01% 12081
2021
Q4 		$119K Sell
84,500
-136,100
-62% -$179K ﹤0.01% 12533
2021
Q3 		$249K Sell
220,600
-35,200
-14% -$49.3K ﹤0.01% 11493
2021
Q2 		$409K Sell
255,800
-35,400
-12% -$62.3K ﹤0.01% 10507
2021
Q1 		$513K Buy
291,200
+51,600
+22% +$118K ﹤0.01% 9617
2020
Q4 		$467K Buy
239,600
+27,100
+13% +$57K ﹤0.01% 8266
2020
Q3 		$508K Buy
212,500
+108,300
+104% +$297K ﹤0.01% 7273
2020
Q2 		$305K Buy
104,200
+57,500
+123% +$165K ﹤0.01% 7879
2020
Q1 		$134K Buy
46,700
+27,100
+138% +$93.7K ﹤0.01% 8387
2019
Q4 		$78K Buy
19,600
+1,800
+10% +$7.84K ﹤0.01% 8638
2019
Q3 		$79K Buy
+17,800
New +$74.4K ﹤0.01% 8575

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citadel Advisors's ADMA Position: Q1 2026 in Review

Citadel Advisors increased its ADMA Biologics (ADMA) stake by 282% in Q1 2026, buying an estimated $67.7M and bringing the position to 5,810,642 shares worth $52.4M. The position accounts for 0.01% of the portfolio, ranked #1316.

Citadel Advisors first reported a position in ADMA in Q1 2018 and has held it in 26 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Citadel Advisors held 5,810,642 shares of ADMA Biologics worth $52.4M as of Q1 2026.
  • Citadel Advisors bought 4,288,072 ADMA Biologics shares in Q1 2026, an estimated $67.7M.
  • ADMA Biologics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1316 holding.
  • Citadel Advisors first reported a position in ADMA Biologics in Q1 2018 and has held it in 26 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.